411 Studies Now Enrolling
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Bronx)
AstraZeneca Vaccine: Study of AZD1222 for the Prevention of COVID-19 in Adults (Bronx)
| Sponsor: | AstraZeneca |
| Enrolling: | Male and Female Patients |
| Study Length: | 24 Months |
| Clinic Visits: | 7 |
| IRB Number: | AAAT2402 |
| U.S. Govt. ID: | NCT04516746 |
| Contact: | Logan Posey: 347-590-7280 / lp2907@cumc.columbia.edu |
Additional Study Information:
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
This study is closed
Do You Qualify?
| Are you 18 years old or older? | Yes | No |
| Have you ever tested positive for Sars-Co-V-2 (Covid-19)? | Yes | No |
| Are you currently pregnant? If N/A select No. | Yes | No |
| Are you preventing pregnancy (i.e. birth control)? If N/A select Yes. | Yes | No |
| Are you willing to travel to the South Bronx for participation in this study? | Yes | No |